-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Preclinical studies at the University of Alberta have shown that giving anti-inflammatory drugs in the nose can help ease the progression of multiple sclerosis.
study showed that providing anti-inflammatory drugs to mice through intransific drugation could prevent damage to brain cells and thus effectively alleviate disease progression.
MS is a devastating disease with a clear and incurable pathogenesis.
Professor Power's lab at the University of Alberta sought to better understand the disease and develop effective treatments.
inflammatory gadgets are multi-protein complexes in cells that over-activate and cause a strong inflammatory response that promotes the progression of a variety of inflammatory diseases, such as MS.
Power Lab explored whether VX-765, an inhibitor of the inflammatory smallbody effect protein caspase-1, could be a strong candidate for MS patients.
in the mouse model, Power dissolves the VX-765 in a liquid and injects the mixture into the nose.
that intranasal dispensing can effectively inhibit demyelination, axon damage and loss.
the loss of myelin and nerves in MS is irreversible, so any treatment that helps slow or prevent this from happening is an important advance in MS research.
nasal dosing does not enter the circulatory system, requires less medicine, can be delivered directly to the brain, and does not break down very quickly.
.